Two FDA-approved compounds, AKT inhibitors and pitavastatin, synergize to induce cell death in triple-negative breast cancer, motivating evaluation of the efficacy of this combination in clinical tria...

REPRIEVE trial finds pitavastatin reduced the risk for heart attack, stroke and other major cardiovascular events by 35%.

This secondary analysis of the Randomized Trial to Prevent Vascular Events in HIV (REPREIVE) randomized clinical trial investigates the associations of statin therapy with protein and gene pathways in...

A widely used statin medication reduced the risk of heart attacks, strokes and other cardiovascular events when given to people with HIV who are at low to moderate risk for cardiovascular disease, acc...

A widely used statin medication reduced the risk of heart attacks, strokes and other cardiovascular events when given to people with HIV who are at low to moderate risk for cardiovascular disease, acc...

Ein Forschungsteam der Korea University hat entdeckt, dass Pitavastatin, ein etabliertes Lipidsenkungsmittel, das anti-apoptotische Protein Mcl-1 direkt hemmt. Dieses Protein ist ein zentraler Überlebensfaktor für therapieresistente triple-negative Brustkrebszellen (TNBC). Pitavastatin eliminiert krebsstammzellähnliche Zellen, unterdrückt Metastasen und stellt die Sensitivität gegenüber Paclitaxel wieder her. Die Ergebnisse deuten auf eine mögliche Repurposing-Strategie für diese aggressive Krebsform hin. Hintergrund zu triple-negativem Brustkrebs Triple-negativer Brustkrebs (TNBC) ist eine der aggressivsten Brustkrebsformen.

Pitavastatin was associated with reduced artery plaque volume and changes in its composition.

Around 58,000 bottles of pitavastatin were recalled due to quality issues, according to the agency.

People with human immunodeficiency virus (HIV, PWH) exhibit increased cardiovascular disease (CVD) risk and accelerated biological aging. REPRIEVE demonstrated that pitavastatin reduced major adverse cardiovascular events (MACE) in antiretroviral therapy (ART)-treated PWH with low-to-moderate traditional cardiovascular risk. It remains unknown whether statin therapy can modulate epigenetic aging in PWH.MethodsWe assessed epigenetic aging biomarkers using DNA methylation profiles from peripheral blood mononuclear cells (PBMCs) in a subset of 99 randomly selected US REPRIEVE participants (65 pitavastatin, 34 placebo) at baseline and 24 months. The primary outcomes were changes in second- and third-generation epigenetic clocks PCGrimAge (trained on mortality risk) and DunedinPACE (trained on rate of age-related multi-organ decline).ResultsMedian chronological age was 57.0 (Q1, Q3: 56, 58) years and 100% of participants demonstrated epigenetic age acceleration, measured by the difference in PCGrimAge and chronological age (median difference 7.08 years [Q1, Q3: 4.69, 9.64]) at entry. Over 24 months, PCGrimAge remained accelerated with no significant differences between treatment arms (P = .89). However, the median pace of aging by the DunedinPACE increased in the placebo arm (0.036, Q1, Q3 [−0.018, 0.10], P = .021) but not in the pitavastatin arm (0.001, Q1, Q3 [−0.031, 0.036], [P = .77]), treatment group difference (P = .049).ConclusionsIn this pilot study of REPRIEVE, epigenetic age acceleration was demonstrated at trial entry. The biological pace of aging increased over 24 months in the placebo group as compared to the statin group. These preliminary findings suggest pitavastatin may prevent an increase in the pace of biological aging in PWH and support further research into statin therapy as a potential intervention to mitigate accelerated aging.Clinical Trials RegistrationNCT02344290 (date of initial registration: 22 January 2015).

Developing high blood pressure doubled the risk of experiencing a cardiovascular event, such as a stroke or heart attack, in the REPRIEVE study of statin treatment in people with HIV, and being assigned to pitavastatin significantly reduced the risk of developing high blood pressure, study investigators reported at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver on Monday.

Of myocardial infarctions (MIs) recorded in 2 large human immunodeficiency virus (HIV) observational studies from North America, approximately half were classified as type 2. In the REPRIEVE clinical trial of pitavastatin versus placebo in people with HIV (PWH) (<3% of participants were from Europe), 20.6% of MIs were type 2. The proportions of type 1 MI (T1MI) and type 2 MI (T2MI) in European PWH are unknown.MethodsThe study included a retrospective record review, ascertainment of prospectively recorded and medically validated MIs, differentiation of T1MI and T2MI, and MI time trend analysis in the Swiss HIV Cohort Study (1 January 2000 to 31 May 2021). Exploratory analysis was performed of the associations of T1MI and T2MI with blood leukocyte count and 2 validated genome-wide coronary artery disease–associated polygenic risk scores (metaGRS and GPSmult).ResultsBetween 2000 and 2021, 16 027 Swiss HIV Cohort Study participants accumulated 181 598 years of follow-up, and 379 had a validated first MI. Of these participants, 359 (94.7%) had T1MI, and 20 (5.3%) had T2MI. Invasive coronary angiography was done in 95% and 60% of participants with T1MI and T2MI, respectively. We found no evidence for increasing or decreasing incidence trends over time for T1MI (P = .86) or T2MI (P = .85). Participants in the highest quintile for leukocyte count, metaGRS, and GPSmult had significantly increased adjusted odds ratios for T1MI; power was limited for detecting associations with T2MI.ConclusionsThe proportion of T2MI in PWH in Switzerland is approximately 5%, consistent with data from the general population and lower than in previous North American reports among PWH.

Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) found small declines in physical function overall among people with HIV (PWH). However, there was substantial individual variability. The purpose of this prespecified exploratory analysis was to identify the PWH at greatest risk for physical function decline.MethodsParticipant-specific annualized rates of change on annually measured chair rise rate, gait speed, the modified Short Performance Physical Battery (composite of the latter 2 plus balance time), and grip strength were estimated from linear mixed-effect models. Change in performance that was below the 20th percentile of the study population in ≥1 measure was classified as physical function decline. Associations between baseline factors and physical function decline were evaluated with log-binomial regression models.ResultsOf 569 participants (81% male, 52% White), the median age (Q1–Q3) was 51 (47–55) years. Half (52%) of the participants had decline in physical function. The risk of decline was higher among females (relative risk [RR], 1.32; 95% CI, 1.12–1.55) and non-Whites (RR, 1.23; 95% CI, 1.05–1.45) and tended to increase with age (50–55 years: RR, 1.04; 95% CI, 0.86–1.26; 55+ vs 40–<50 years: RR, 1.17; 95% CI, 0.98–1.39). In models adjusted for age, sex, and race, we found greater risk of decline among those with history of depression treatment, higher body mass index (BMI), preexisting functional impairment, frailty (by index), and higher baseline high-sensitivity C-reactive protein and interleukin-6 levels.ConclusionsPWH with history of depression treatment, high BMI, or levels of inflammation and those showing early signs of functional impairment may be at higher risk of physical function decline and should be targeted for early interventions to preserve physical function with aging.

Of myocardial infarctions (MI) recorded in two large HIV observational studies from North America, approximately half were classified as type 2. In the REPRIEVE clinical trial of pitavastatin vs. placebo in people with HIV (<3% of participants were from Europe), 20.6% of MIs were type 2. It is unknown what the proportion of type 1 and type 2 MI (T1MI, T2MI) is in European people with HIV.MethodsRetrospective chart review, ascertainment of prospectively recorded and medically validated MIs, differentiation of T1MI and T2MI, MI time trend analysis in the Swiss HIV Cohort Study (01.01.2000-31.05.2021). Exploratory analysis of the associations of T1MI and T2MI with blood leukocyte count and two validated genome-wide coronary artery disease (CAD)-associated polygenic risk scores (metaGRS and GPSMult).ResultsBetween 2000 and 2021, 16’027 SHCS participants accumulated 181’598 years of follow-up, and 379 had a validated first MI. Of these, 359 (94.7%) participants had T1MI, and 20 (5.3%) participants had T2MI. Invasive coronary angiography was done in 95% and 60% of participants with T1MI and T2MI, respectively. We found no evidence for increasing or decreasing incidence trends over time for T1MI (p=0.863) and T2MI (p=0.852). Participants in the highest quintile of leukocyte count, meta-GRS, and GPSMult had significantly increased adjusted odds ratio for T1MI; power was limited for detecting associations with T2MI.ConclusionsThe proportion of T2MI in people with HIV in Switzerland is approximately 5%, consistent with data from the general population, and lower than in previous North American reports among people with HIV.

먼저 해당 글은 전문가의 글이 아니므로 오류가 있을수가 있으니 반드시 전문가와 상의 하시길 바라겠습니다.오늘은 콜레스테롤 수치가 높게 나오거나 이상지질혈증 진단을 받았으면 약물을 하게 되면 복용하게 되는 악인 이바틴정 2mg 효능과 성분 복용법과 부작용에 대해서 알아보겠습니다.타바스타틴(Pitavastatin) 성분을 사용하는 스타틴계 고지혈증 치료제입니다...

Pitavastatin was associated with reduced artery plaque volume and changes in its composition.